Friday 16 October 2026
Export ALXO’s income statement to Excel — free account
ALX Oncology Holdings Inc.
ALXO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.06
0.06
+6.00%
Follow ALXO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 28.01 | 20.31 | 5.82 | 3.94 | 1.19 | 0.40 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 117.45 | 91.52 | 22.40 | 15.93 | 17.83 | 2.27 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 15 | 23 | 43 | 58 | 72 | 80 | 43 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.32 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 2 | 5 | 1 | — | — | — | — | — | ||||
| Gross margin, % | — | — | 9.05 | 9.09 | 9.05 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (14) | (19) | (45) | (83) | (123) | (161) | (135) | (102) | |||||
| EBT margin, % | — | — | (662.12) | (400.52) | (3,849.32) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (14) | (19) | (46) | (83) | (123) | (161) | (135) | (102) | |||||
| Depreciation | — | — | 0 | 0 | 1 | 0 | (1) | (5) | (4) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.75 | 1.56 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (4.99) | (6.26) | (2.76) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) | |||||
| Cash flow | — | — | (4.79) | (4.63) | (2.07) | (1.69) | (2.19) | (3.03) | (2.34) | (1.57) | |||||
| Capex | — | — | (0.24) | (0.11) | 0.00 | (0.12) | (0.04) | (0.03) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | (5.03) | (4.75) | (2.07) | (1.81) | (2.23) | (3.06) | (2.35) | (1.57) | |||||
| Book value | — | — | 0.00 | (22.96) | 23.25 | 9.01 | 6.47 | 4.41 | 2.18 | 0.48 | |||||
| Shares, m | — | — | 3 | 3 | 18 | 40 | 41 | 43 | 52 | 54 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — | ||||
| P/S | — | — | 25.44 | 25.44 | 653.57 | — | — | — | — | — | |||||
| P/B | — | — | 0.00 | 0.00 | 3.71 | — | — | — | — | — | |||||
| EV/Sales | — | — | 0.67 | 0.67 | 477.83 | — | — | — | — | — | |||||
| EV/FCF | — | — | (0.12) | (0.12) | (30.40) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (13) | (14) | (38) | (68) | (89) | (130) | (122) | (84) | ||||
| Capex | — | — | (1) | 0 | 0 | (5) | (1) | (1) | 0 | 0 | |||||
| Free cash flow | — | — | (14) | (15) | (38) | (73) | (91) | (132) | (122) | (84) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 8 | 5 | 430 | 352 | 243 | 153 | 116 | 26 | ||||
| Total debt | — | — | — | 5 | — | 3 | 10 | 10 | 10 | 10 | |||||
| Net debt | — | — | (8) | (4) | (434) | (361) | (256) | (173) | (118) | (35) | |||||
| Shareholders’ equity | — | — | — | (71) | 430 | 363 | 263 | 190 | 114 | 26 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (435.95) | (22.81) | (20.45) | (35.97) | (58.58) | (69.10) | (98.34) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (2,661.67) | (1,036.13) | (640.53) | 0.00 | 0.00 | |||||
| ROE | — | — | 28.43 | 38.02 | (28.36) | (21.05) | (39.42) | (70.97) | (88.91) | (145.70) | |||||
Negative figures in brackets.
Fiscal years to Dec 2020 · latest quarter Dec 2020
Charts ten years each
ALX Oncology Holdings Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MSLE Satellos Bioscience Inc. | $145.1M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $138.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | |
| AVXL Anavex Life Sciences Corp. | $137.2M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | Compare |
| KRRO Korro Bio, Inc. | $137.1M | — (loss-making) | — (loss-making) | −86.28% (below 0%: shrinking) | n/m | +12.07% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ANTX AN2 Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CUE Cue Biopharma, Inc. | $135.6M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TLSA Tiziana Life Sciences Ltd | $134.7M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $120.8M | — (loss-making) | — | — | n/m | +43.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $136.5M | — | — | −86.28% | — | +15.05% | 0.00% | 0.00% |
ALX Oncology Holdings Inc. (ALXO) key facts
- ALX Oncology Holdings Inc. (ALXO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ALXO traded at $1.06, a market capitalization of $138.3 million.
- Return on equity was −145.7% and debt-to-equity 0.07.
ALX Oncology Holdings Inc. (ALXO) Latest News
No news at this impact. Lower the threshold for more.